SANTIAGO
MORENO GUILLÉN
Investigador hasta 2007
![Foto de SANTIAGO](/img/nophoto.png)
![Foto de Universitat Autònoma de Barcelona](/img/noimage_org.png)
Universitat Autònoma de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (10)
2018
-
Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522
2016
-
Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma
Hepatology, Vol. 63, Núm. 2, pp. 488-498
2015
-
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
AIDS, Vol. 29, Núm. 16, pp. 2155-2159
2014
-
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
AIDS, Vol. 28, Núm. 16, pp. 2461-2473
2010
-
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study
The Lancet, Vol. 376, Núm. 9738, pp. 340-345
-
The future of antiretroviral therapy: Challenges and needs
Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 5, pp. 827-835
2008
-
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 2, pp. 234-245
2007
-
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: The CORAL-1 multicentre pilot study
Journal of Viral Hepatitis, Vol. 14, Núm. 10, pp. 704-713
2005
-
Treatment-limiting toxicities associated with nucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study
Current Therapeutic Research - Clinical and Experimental, Vol. 66, Núm. 2, pp. 117-129
2003
-
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836